TG Therapeutics, Inc. (TGTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 12, 2025, details the results of TG Therapeutics, Inc.'s 2025 Annual Meeting of Stockholders held on June 12, 2025. The meeting was conducted via an online platform. Stockholders representing 118,430,391 shares (74.58% of 158,776,296 outstanding shares) were present, establishing a quorum.
Key Financial Metrics
This filing is a corporate governance report regarding shareholder votes and does not contain financial performance data. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
All four proposals presented at the Annual Meeting were approved by the stockholders. The specific voting outcomes were as follows:
- Proposal 1 (Election of Directors): All six nominees were elected. Support varied significantly among directors:
- Michael S. Weiss: 85.55% For
- Laurence N. Charney: 80.56% For
- Kenneth Hoberman: 60.52% For
- Daniel Hume: 58.89% For
- Yann Echelard: 58.63% For
- Sagar Lonial, MD: 54.12% For
- Proposal 2 (Ratification of Auditors): KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 117,836,086 votes For versus 442,199 votes Against.
- Proposal 3 (Executive Compensation): The advisory vote to approve named executive officer compensation passed with 47,864,737 votes For and 39,988,402 votes Against.
- Proposal 4 (Equity Plan Amendment): Stockholders approved an amendment to the 2022 Incentive Plan to increase authorized shares from 17,000,000 to 22,000,000. The vote was 82,034,592 For versus 5,788,439 Against.
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the procedural outcomes of the shareholder meeting.
Key Facts for Investor Verification
- Verify the significant "Withheld" votes for directors Yann Echelard, Kenneth Hoberman, Daniel Hume, and Sagar Lonial, MD, all of whom received less than 61% support.
- Confirm the approval of the 5,000,000 share increase in the 2022 Incentive Plan, which may impact future dilution.
- Note the substantial "Against" vote (approx. 45%) on the executive compensation advisory proposal, indicating notable shareholder dissent regarding pay practices.
- Review the definitive proxy statement (Schedule 14A) filed on April 30, 2025, for detailed context on the director elections and compensation rationale.